{
  "id": "5c73ad047c78d6947100008e",
  "type": "summary",
  "question": "What is the mechanism of action of Inclisiran?",
  "ideal_answer": "Inclisiran, a novel, synthetic, siRNA molecule, inhibits PCSK9 synthesis in hepatocytes. Inclisiran targets intracellular PCSK9 synthesis specifically, resulting in a dose-dependent, long-term, significant reduction in LDL-C.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28736830",
    "http://www.ncbi.nlm.nih.gov/pubmed/29424317",
    "http://www.ncbi.nlm.nih.gov/pubmed/29451410",
    "http://www.ncbi.nlm.nih.gov/pubmed/29516321",
    "http://www.ncbi.nlm.nih.gov/pubmed/28306389",
    "http://www.ncbi.nlm.nih.gov/pubmed/30487231",
    "http://www.ncbi.nlm.nih.gov/pubmed/27959715",
    "http://www.ncbi.nlm.nih.gov/pubmed/29735484",
    "http://www.ncbi.nlm.nih.gov/pubmed/30375244",
    "http://www.ncbi.nlm.nih.gov/pubmed/30011788",
    "http://www.ncbi.nlm.nih.gov/pubmed/29850255"
  ],
  "snippets": [
    {
      "text": "Inclisiran is a promising RNA-based therapy that promotes the degradation of PCSK9 mRNA transcripts and has similar efficacy to mAbs, but with a much longer duration of action.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28736830",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently marketed monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9) have shown the way towards innovation, while other ways of PCSK9 inhibition like small interfering RNA (Inclisiran) are already being tested. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29424317",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Inclisiran, a novel, synthetic, siRNA molecule, inhibits PCSK9 synthesis in hepatocytes. Inclisiran targets intracellular PCSK9 synthesis specifically, resulting in a dose-dependent, long-term, significant reduction in LDL-C. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29451410",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: To our knowledge, inclisiran was the first agent composed of small interfering RNAs (siRNAs) to be preliminarily used to reduce proatherogenic lipoprotein cholesterol levels. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29516321",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: The ORION-1 trial (Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol [LDL-C]) demonstrated that inclisiran, an siRNA therapeutic that targets protease proprotein convertase subtilisin/kexin type 9 mRNA within hepatocytes, produces significant low-density lipoprotein cholesterol reduction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29735484",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The development of inclisiran, siRNA silencer targeting PCSK9 gene, is a one step forward in these endeavors. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29850255",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inclisiran is a long-acting, synthetic siRNA directed against PCSK9 and it has been shown to significantly decrease hepatic production of PCSK9 and cause a marked reduction in LDL-C levels. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30011788",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inclisiran is a novel drug that inhibits PCSK9 synthesis specifically in the liver, harnessing the natural mechanism of RNAi.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30375244",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nInclisiran (ALN-PCSsc) is a long-acting RNA interference (RNAi) therapeutic agent that inhibits the synthesis of proprotein convertase subtilisin-kexin type 9 (PCSK9), a target for the lowering of low-density lipoprotein (LDL) cholesterol.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27959715",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\nInclisiran produces significant and prolonged reductions in atherogenic lipoproteins, suggesting that inhibiting the synthesis of protease proprotein convertase subtilisin/kexin type 9 through siRNA may be a viable alternative to other approaches that target protease proprotein convertase subtilisin/kexin type 9.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29735484",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inclisiran targets intracellular PCSK9 synthesis specifically, resulting in a dose-dependent, long-term, significant reduction in LDL-C. Inclisiran has been well tolerated and safe, without severe adverse events so far.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29451410",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Areas covered: PCSK9 inhibition has emerged as a promising new therapeutic strategy to reduce LDL-C. Inclisiran, a novel, synthetic, siRNA molecule, inhibits PCSK9 synthesis in hepatocytes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29451410",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nThe ORION-1 trial (Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol [LDL-C]) demonstrated that inclisiran, an siRNA therapeutic that targets protease proprotein convertase subtilisin/kexin type 9 mRNA within hepatocytes, produces significant low-density lipoprotein cholesterol reduction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29735484",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently marketed monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9) have shown the way towards innovation, while other ways of PCSK9 inhibition like small interfering RNA (Inclisiran) are already being tested.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29424317",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inclisiran inhibits translation of PCSK9 mRNA and thus switches off PCSK9 production and provides advantages over monoclonal antibodies with an infrequent dosing interval of twice a year to reduce LDL-C by over 50%.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29451410",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inclisiran is a long-acting, synthetic siRNA directed against PCSK9 and it has been shown to significantly decrease hepatic production of PCSK9 and cause a marked reduction in LDL-C levels.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30011788",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program.Inclisiran is a novel drug that inhibits PCSK9 synthesis specifically in the liver, harnessing the natural mechanism of RNAi. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30375244",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia.The discovery of proprotein convertase subtilisin-kexin type 9 (PCSK9), a serine protease which binds to the low-density lipoprotein (LDL) receptors and targets the receptors for lysosomal degradation, offered an additional route through which plasma LDL-cholesterol (LDL-C) levels can be controlled. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30011788",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30487231",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.In our trial, inclisiran was found to lower PCSK9 and LDL cholesterol levels among patients at high cardiovascular risk who had elevated LDL cholesterol levels. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28306389",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Inclisiran targets intracellular PCSK9 synthesis specifically, resulting in a dose-dependent, long-term, significant reduction in LDL-C. Inclisiran has been well tolerated and safe, without severe adverse events so far.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29451410",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This review discusses current PCSK9 inhibitors and the results of phase I and II clinical trials of inclisiran.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29451410",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Areas covered: PCSK9 inhibition has emerged as a promising new therapeutic strategy to reduce LDL-C. Inclisiran, a novel, synthetic, siRNA molecule, inhibits PCSK9 synthesis in hepatocytes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29451410",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inclisiran (ALN-PCSsc) is a long-acting RNA interference (RNAi) therapeutic agent that inhibits the synthesis of proprotein convertase subtilisin-kexin type 9 (PCSK9), a target for the lowering of low-density lipoprotein (LDL) cholesterol.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27959715",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}